Navigation Links
U.S. Senate Urged to Increase Federal Funding for Research into Hereditary Angioedema, a Rare and Serious Genetic Disorder
Date:6/12/2012

HONOLULU, June 12, 2012 /PRNewswire/ -- Today, the U.S. Hereditary Angioedema Association (HAEA) announced that it has appealed to the U.S. Senate Appropriations Committee to increase federal research funding for hereditary angioedema (HAE), a rare and potentially fatal genetic disorder. As a part of the Committee's annual "public witness testimony" hearing, which allows outside experts and stakeholders to advocate for fiscal year 2013 funding, Anthony J. Castaldo, president of the HAEA, called for the inclusion of HAE in the peer-reviewed, medical research program sponsored by the Department of Defense.

"Even with our current understanding of HAE, a significant unmet medical need still exists, and there is a critical need for additional research into the causes and treatment of this serious and life-threatening disorder," said Castaldo. "Our hope is that by encouraging the inclusion of HAE in the important medical research conducted by the Department of Defense, we can expedite accurate diagnosis and effective treatment for all HAE patients."

The HAEA testimony is part of the Association's ongoing political advocacy efforts to highlight and enhance recognition of the significant need for both increased education regarding HAE, and further research aimed at improving diagnosis and treatment options for patients.

HAE involves episodes of edema, or swelling, in the face, feet, hands, throat and abdomen.  For many patients, HAE is caused by a defect or deficiency of the blood protein C1-esterase inhibitor.  However, swelling symptoms identical to HAE have also been identified in families where patients have normal C1-esterase inhibitor levels, and there is a critical need for additional research into the genetic and biochemical markers for this form of HAE.  

HAE attacks that involve the face or throat can result in airway closure, asphyxiation and, if untreated, death. Because the disease is very rare, it is not uncommon for patients to remain undiagnosed for many years, receive inappropriate diagnoses or undergo unnecessary exploratory surgery.  Experts estimate that HAE occurs in 1 in 10,000 to 1 in 50,000 people. Medications approved by the Food and Drug Administration (FDA) for treating the symptoms of HAE are now available in the U.S.

For more information about the HAEA's public policy program, please visit www.HAEA.org.

About the U.S. Hereditary Angioedema Association (HAEA)
Founded and staffed by HAE patients and HAE patient caregivers, the HAEA is a non-profit patient advocacy organization dedicated to serving angioedema patients. The Association provides HAE patients and their families with a support network and a wide range of services including physician referrals and individualized patient support. The HAEA's goal is to increase awareness of hereditary angioedema by providing patients and physicians with authoritative and readily accessible information. The HAEA is committed to advancing and conducting clinical research designed to improve the lives of HAE patients and ultimately find a cure. To learn more about the HAEA or join the Association, visit www.HAEA.org, email info@haea.org or call 866-798-5598.

Contact:
Laura de Zutter
MCS Healthcare Public Relations on behalf of the HAE Association
800-477-9626
laurad@mcspr.com


'/>"/>
SOURCE U.S. Hereditary Angioedema Association (HAEA)
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
2. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
3. European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan
4. Increased fertility rate for IVF patients achieved by new equipment design
5. HPV Testing for Cervical Cancer Risk Patients set to Increase
6. GeNO LLC Makes Significant Additions to Management Team to Increase Capability and Talent
7. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
8. Downsizing and the Need for Increased Selling Effectiveness Fuel Delta Points Growth
9. Voltage increases up to 25 percent observed in closely packed nanowires at Sandia Labs
10. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
11. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing ... supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. , ...
(Date:12/2/2016)... leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI HIV ... http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton Health ... Self Test to 350 pharmacy representatives in Nairobi and Mombasa, ...
(Date:11/30/2016)... 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... is excited to announce the formation of EyGen, ... preclinical ophthalmology assets through proof of concept. EyGen,s ... by Portage Pharmaceuticals Limited and being developed for ... and anterior segment diseases. This agent has the ...
(Date:11/30/2016)... , Nov. 30, 2016  Tempus, a technology ... care, and Penn,s Abramson Cancer Center have partnered ... positive response to immunotherapy treatment based on next ... As part of a research collaboration, Tempus will ... melanoma cancer patient data to Penn. Utilizing next-generation ...
Breaking Biology Technology:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
(Date:11/15/2016)... -- Research and Markets has announced the addition of ... to their offering. ... The global bioinformatics ... USD 6.21 Billion in 2016, growing at a CAGR of 21.1% ... market is driven by the growing demand for nucleic acid and ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
Breaking Biology News(10 mins):